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Transplantation of stem cell-derived insulin producing cells (IPCs) has been proposed as an alternative 
to islet transplantation for the treatment of diabetes mellitus. However, current IPC differentiation 
protocols are focused on generating functional cells from the pluripotent stem cells and tend to 
rely on multistep, long-term exposure to various exogenous factors. In this study, we addressed 
the observation that under stress, pancreatic β-cells release essential components that direct the 
differentiation of the bone marrow nucleated cells (BMNCs) into IPCs. Without any supplementation 
with known differentiation-inducing factors, IPCs can be generated from BMNCs by in vitro priming 
for 6 days with conditioned media (CM) from the β-cells. In vitro primed BMNCs expressed the β-cell-
specific transcription factors, as well as insulin, and improved hyperglycemia and glucose intolerance 
after transplantation into the streptozotocin-induced diabetic mice. Furthermore, we have found that 
components of the CM which trigger the differentiation were enclosed by or integrated into micro 
particles (MPs), rather than being secreted as soluble factors. Identification of these differentiation-
directing factors might enable us to develop novel technologies required for the production of clinically 
applicable IPCs.
Diabetes mellitus (DM) is characterized by chronic hyperglycemia resulting from the defects in insulin secretion, 
insulin action, or both. Type 1 DM results from autoimmune destruction of the β-cells in the pancreatic islets1,2, 
whereas more common type 2 DM results from insulin resistance in the peripheral tissues and subsequent β-cell 
dysfunction3–5. Although islet transplantation can achieve better glycemic control than insulin therapy6,7, many 
complicated issues including shortage of islet donors and necessity of immune suppression, have hampered this 
treatment’s widespread use.
During the last several decades, extensive research has been focused on the treatment of type 1 DM based on 
the generation of the surrogate insulin producing cells (IPCs) from the stem cells. Many research groups have 
developed stepwise differentiation protocols that mimic the developmental paradigms to differentiate the pluripo-
tent stem cells (PSC) into the IPC progenitors that are capable of maturation in vivo8–13. However, IPC-generating 
protocols involve multistep exposure to exogenous soluble factors and/or small molecules for extended periods 
of time. Moreover, PSC-derived IPCs are not free from tumorigenesis after transplantation14. For these reasons, 
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Figure 1. BMNCs differentiate into IPCs in vivo. (A) Outline of the experimental procedure to test the 
contribution of BMNCs in the generation of IPCs in STZ-induced diabetic mice. (B) Immunofluorescent 
staining of pancreatic tissues harvested from chimeric C57BL/6 mice bearing BMNCs from MIP-Luc/
GFP mice. Each vertical panel show representative staining of the pancreas harvested from control (−STZ) 
and STZ- treated mice (24, 34 and 48 days after STZ injection, +STZ). GFP-expressing cells are present 
in some islets and almost all of the GFP expressing cells are stained for insulin (yellow, upper right) and 
PDX-1 (lower right). There are no GFP expressing cells in the islets of normal chimeric mice. Magnification 
400×. Immunofluorescent staining for DAPI (blue) and GFP (green) with insulin (red) or PDX-1 (red) in 
pancreatic tissues. Additional single color images are provided in Supplementary Fig. S1A. (C) Representative 
immunofluorescent staining of small intestinal tissues in control (vehicle treated, −STZ) or diabetic-MIP-Luc/
GFP mice (STZ treated, +STZ) on day 18. Note the appearance of insulin and GFP double positive cells in the 
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adult stem cells might be the preferred cell source for IPCs. Innovative differentiation technologies, which can 
effectively, efficiently, and reproducibly direct cell fate change, must be developed for clinical application in the 
diabetic cell therapy.
Extracellular vesicles (EVs) are generally referred to as exosomes, microvesicles, or microparticles (MPs), and 
have been implicated in numerous aspects of intercellular communication15–19. Recently, the pathophysiological 
roles of EVs are beginning to be recognized20–23. Moreover, it is worth noting that the EV-mediated transfer of the 
cellular components shed from the damaged tissues can reprogram the stem cells to acquire phenotypic features 
of the injured tissue cells24–26.
In this study, we report that bone marrow nucleated cells (BMNCs) can be differentiated into IPCs that can 
improve hyperglycemia in the streptozotocin (STZ)-induced diabetic mice after systemic infusion. In vitro prim-
ing with conditioned media (CM) prepared from the culture supernatants of the syngeneic or xenogeneic β-cells 
under stress conditions can direct the BMNCs to express the β-cell-specific proteins, including insulin, C-peptide, 
PDX-1, MafA, and Nkx6.1, within 6 days. Moreover, ex vivo primed BMNCs improved hyperglycemia and glu-
cose intolerance after systemic infusion in the diabetic mice. We also found that IPC differentiation was spe-
cifically mediated by the MPs shed from the β-cells maintained under stress conditions because priming with 
MP-depleted CM did not induce IPC generation. These results suggest that identification of the MP-associated 
differentiation-directing factors might enable us to establish novel technologies for the production of IPCs.
Results
In vivo differentiation of BMNCs into IPCs. It has been previously reported that BMNCs significantly 
contribute to adult β-cell renewal in mice27–31, but other reports have contradicted these findings32,33. Initially, 
we tested whether BMNCs can differentiate into IPCs. We generated chimeric C57BL/6 mice harboring BMNCs 
from the insulin promoter luciferase/GFP transgenic (MIP-Luc/GFP) mice and then treated the mice with strep-
tozotocin (STZ) to destroy the β-cells, while control mice were treated with the same volume of vehicle (Fig. 1A). 
We then analyzed pancreatic sections by immunofluorescence staining with antibodies against GFP, insulin, and 
PDX-1 at different time points. It should be noted that the GFP-expressing cells began to appear approximately 24 
days after STZ treatment, and the number of the GFP-positive cells increased up to 48 days after STZ treatment 
(Figs 1B; S1A; Table S1). These results implied that the GFP and insulin double positive cells were differentiated 
from BMNCs that were mobilized from the bone marrow. We also detected the GFP and insulin double positive 
cells in the small intestine on day 18 in MIP-Luc/GFP mice treated with STZ (Figs 1C; S1B), consistent with 
an increase in the luciferase signal in the intestine of these mice (Fig. S1C). These phenomena are similar to 
previous reports that have demonstrated heterotopic neogenesis of IPCs in diabetic animal models, such as STZ-
treated mice34–36. We hypothesized that damaged β-cells might shed some factors that direct the differentiation 
of BMNCs into IPCs. Thus, we prepared conditioned media (CM) from the culture supernatant of an insulinoma 
cell line maintained under stress at low levels of glucose and serum. We mixed the CM with Matrigel at a ratio 
of 1:1 and transplanted the mixture into the subcutaneous region of the healthy chimeric MIP-Luc/GFP mice. 
Immunofluorescence staining of the Matrigel platforms harvested on day 18 after transplantation revealed newly 
differentiated insulin and GFP double positive cells only in the Matrigel platforms containing CM of syngeneic 
MIN-6 insulinoma cells (Fig. 1D). However, the CM-free Matrigel or the Matrigel platforms containing CM of a 
clonal endothelial bEND.3 cell line did not show any positive cells (Fig. S1D). These results indicate that BMNCs 
were capable of differentiating into IPCs in response to the signals or components shed from the damaged β-cells.
In vitro differentiation of BMNCs into IPCs. We developed a simple and reproducible IPC-generating 
priming protocol (Fig. 2A) after extensive testing of various culture conditions. Priming with CM prepared from 
the culture supernatants of the syngeneic (MIN-6) or xenogeneic (INS-1) insulinoma cell lines directed the 
MIP-Luc/GFP derived BMNCs to express GFP within 6 days (Fig. 2B). However, microparticles (MPs)-depleted 
CM, in which large particles over 100 kDa have been removed, did not trigger GFP expression. This finding sug-
gested that MPs shed from the β-cells under stress conditions were responsible for the differentiation of BMNCs 
into IPCs. Gene expression analysis of the primed BMNCs (Fig. 2C) revealed an increase in the mRNA expres-
sion of Ngn3, PDX-1, MafA, and Nkx6.1 which are known to directly regulate insulin transcription through the 
formation of a complex with transcriptional coactivators on the insulin promoter37. We observed similar priming 
effects with CM from the primary islets isolated from the xenogeneic rats (Fig. S2A). However, the BMNCs 
primed with normal culture media of MIN-6 (MIN-6 non-CM) or CM from a clonal endothelial bEND.3 did not 
express those β-cell specific genes (Fig. S2B). Primed BMNCs further maintained for 6 days in the absence of CM 
continued to express GFP (Fig. 2D).
Pancreatic β-cell derived components induce the fate change of BMNCs into IPCs. BMNCs 
from the wild type C57BL/6 mice primed with MIN6-CM expressed the β-cell markers, including C-peptide, 
PDX-1, and MafA, within 6 days and could be maintained for an additional 6 days in the absence of CM (Figs 3A; 
lamina propria of the intestinal villi of diabetic mice and the absence of these cells in control mice. DAPI, GFP, 
and insulin staining are shown in blue, green, and red respectively. Magnification 1,000×. Additional single 
color images are provided in Supplementary Fig. S1B. (D) Representative immunofluorescent staining of a 
Matrigel graft harvested 18 days after transplantation as described in the supplementary methods. GFP (green) 
and insulin (red) double positive cells are present in the Matrigel graft containing CM of β-cells (lower panel) 
but not in the CM-free graft (upper panel). Magnification 1,000×. All images were acquired with an Olympus 
FluoView FV1000 confocal microscope.
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Figure 2. BMNCs differentiate into IPCs in vitro. (A) Outline of in vitro differentiation 
(priming + maintenance) protocol ruling out known differentiation inducing factors. (B) FACS analysis of 
BMNCs after 6 days of priming with MIN-6 CM (left), INS-1 CM (middle), and MPs-depleted MIN-6 CM 
(right). Representative histograms illustrating GFP expression as a marker of insulin promoter activation. 
Freshly prepared BMNCs of MIP-Luc/GFP mice were primed with differently prepared CM (blue line) for 6 
days and GFP expression was compared to control BMNCs (red) in non-primed culture media. Priming with 
CM prepared from the supernatant of syngeneic β-cells (MIN-6) or xenogeneic β-cells (INS-1) directed GFP 
expression in BMNCs from MIP-Luc/GFP mice. BMNCs primed with MP-depleted MIN-6 CM do not express 
GFP as do control cells (red line). The text indicates the percentage of GFP expression compared to non-primed 
control cells. (C) Gene expression analysis of cells harvested at the end of 6 days of priming, compared with 
syngeneic (MIN-6 CM) or xenogeneic (INS-1 CM) β-cells as well as freshly isolated murine BMNCs (control). 
CM-primed BMNCs express β-cell markers (insulin 2, Ngn3, PDX-1, MafA, and Nkx6.1) but not glucagon. 
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S3). In contrast to this result, the expression of the β-cell markers in the BMNCs without CM from the insuli-
noma cell lines was negligible. Although the control cells were weakly stained for insulin, they were negative for 
C-peptide, PDX-1, and MafA suggesting a possibility of a nonspecific staining or contamination from insulin 
present in the culture medium serum (Fig. 3A). Gene expression analysis of the primed BMNCs maintained in 
the absence of CM (Fig. 3B) also indicated that insulin was produced by the primed BMNCs.
Systemic infusion of primed BMNCs improves hyperglycemia in the diabetic mice. We tested 
whether primed BMNCs can regulate the blood glucose levels after systemic infusion of the primed BMNCs from 
the MIP-Luc/GFP mice into the diabetic mice through the tail vein (Fig. 4A). The baseline glucose levels of the 
STZ-induced diabetic mice were controlled by transplanting slow-release insulin pellets for 14 days. Systemically 
infused INS-1 CM-primed BMNCs, as well as MIN-6 CM-primed BMNCs, reproducibly protected the mice from 
a progressive decrease in body weight and maintained their blood glucose at lower levels compared with the cor-
responding levels in the diabetic mice transplanted with non-primed control BMNCs (Fig. 4B). Moreover, mice 
transplanted with the primed BMNCs showed significantly lower fasting blood glucose levels and improved glu-
cose tolerance 56 days after transplantation compared to mice transplanted with non-primed BMNCs (Fig. 4C). 
Systemic infusion of the primed BMNCs also alleviated polyphagia and polydipsia frequently found in the dia-
betic mice (data not shown). We analyzed the pancreas and the intestinal tissues of the diabetic mice transplanted 
with INS-1 CM-primed BMNCs by immunofluorescence staining with antibodies against GFP and pancreatic 
α and β cell markers. We hardly observed GFP positive cells in the pancreas. Notably, few insulin single positive 
cells were found in the pancreas, indicating that residual or regenerated β cells could be presumed absent in the 
pancreatic tissues (Figs 4D; S4). On the other hand, we found a lot of GFP/insulin double positive cells scattered 
in the lamina propria of the intestinal villi, indicating that most transplanted cells moved to the intestine rather 
than pancreas. GFP/C-peptide double staining showed that insulin was properly processed in these cells (Figs 4D; 
S5A,B). Glucagon-expressing cells were rarely detected in the intestine, suggesting that the transplanted cells did 
not differentiate into α cells (Figs 4D; S5C). Although some populations of the intestinal cells are known to dif-
ferentiate into IPCs38–40, GFP expression analysis revealed that transplanted cells, rather than endogenous cells, 
were the origin of the insulin and C-peptide double positive cells found in the intestine. However, we could not 
find any GFP-expressing cells in the pancreas or intestine of the diabetic mice transplanted with the control cells 
(data not shown).
Discussion
In this study, we found that BMNCs can differentiate into IPCs in vivo, as demonstrated by the neogenesis of the 
GFP and insulin double positive cells in the STZ-treated MIP-Luc/GFP chimeric mice. This finding is in line with 
previous reports that showed the differentiation of BMNCs into functional cells in the injured tissues24–26,41,42. We 
also generated BMNCs-derived IPCs which express the β-cell-specific markers by in vitro priming of the freshly 
prepared BMNCs with CM prepared from the β-cell lines for 6 days. Furthermore, we demonstrated that trans-
plantation of the in vitro-primed BMNCs contributed to blood glucose control in the diabetic mice and improved 
the fasting blood glucose levels and glucose tolerance, two months after the transplantation.
We established a simple and effective protocol for differentiation of IPCs from BMNCs, which has several 
advantages. First, freshly isolated BMNCs were utilized, unlike other protocols that use multiple stem cell sources 
manipulated in the culture dishes, including ESCs, induced pluripotent stem cells (iPCs), and adult stem cells, 
such as MSCs and HSCs. Additionally, BMNCs were easily primed with the CM prepared from the cultured β-cell 
lines without any chemical or cytokine supplements. Furthermore, only 6-day priming with CM was enough to 
differentiate the BMNCs into insulin-producing cells. We observed similar priming effects with the CM from the 
islets isolated from the xenogeneic rats but not with the CM from a cultured endothelial cell line. These results are 
in accordance with our previous report that liver conditioned media contribute to the differentiation of the bone 
marrow cells to hepatocytes43.
We assumed that β-cell-derived MP-associated factors were responsible for IPC differentiation, since 
MP-depleted CM did not trigger GFP expression in the BMNCs obtained from the MIP-Luc/GFP mice (Fig. 2B). 
Previously, we have shown that the use of the extracellular vesicle-mimetic nanovesicles derived from a mouse 
β-cell line can differentiate the bone marrow cells into IPCs in vivo and effectively regulate the blood glucose lev-
els in the STZ-induced diabetic mice44. These results suggest that β-cell-derived factors in CM or MP might play 
an important role in the differentiation of IPCs from BMNCs.
More importantly, insulin-producing cells, insulin/GFP double positive cells as well as insulin single positive 
ones, were hardly found in the pancreas. It suggest that residual or regenerated β cells can be presumed absent 
in the pancreatic tissues, and the potential effect of resident regenerated cells is negligible. Interestingly, primed 
BMNCs infused via tail vein were found in the lamina propria of the intestinal villi, as demonstrated by the pres-
ence of the GFP/C-peptide and insulin/C-peptide double positive cells. The exact mechanism of engraftment of 
the transplanted primed BMNCs in the intestinal tissues is not known. However, we should note that diabetic cell 
Freshly isolated BMNCs served as controls. Data are presented as mean ± S.E.M. of three independent 
experiments. *p < 0.05 for primed BMNCs versus. Freshly isolated BMNCs. (D) Primed BMNCs, which were 
further maintained for 6 days in the absence of CM still express GFP. Primed BMNCs were thoroughly washed 
with PBS and maintained for 6 more days under static conditions as described in (A). GFP expression under a 
fluorescent microscope is comparable to that of β-cells isolated from the pancreas of MIP-Luc/GFP mice and 
protein expression was confirmed by western blotting. Fluorescent images were obtained using a Nikon Eclipse 
Ti inverted fluorescent microscope.
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therapy does not require functional integration of transplanted cells into pancreatic tissues because transplanta-
tion into ectopic sites can also provide an adequate insulin replacement to control hyperglycemia45.
An earlier study by Chen et al. reported that ectopic expression of Pdx1, MafA, and Neurog3 in the intesti-
nal crypts results in their conversion into cells with β-like feature called “neoislets”, and importantly, intestinal 
neoislets are glucose-responsive and able to ameliorate hyperglycemia in STZ-induced diabetic mice. Talchai et al., 
based on the combination of genetic and cellular approaches of Foxo1 ablation, concluded that somatic abla-
tion of Foxo1 in Neurog3-expressing (Neurog3+) enteroendocrine progenitors give rise to gut insulin-producing, 
glucose-responsive cells that express markers of mature β cells and secrete bioactive insulin as well as C-peptide. 
Figure 3. Primed BMNCs are further maintained in the absence of CM. Representative immunofluorescent 
staining of MIN-6 CM-primed BMNCs isolated from wild type C57BL/6 mice and comparable control cells at 
the end of maintenance (A). Both PDX-1 and MafA expression were found not only in the nucleus but also in 
the cytoplasm. Although the control cells were also weakly positive only for insulin staining, C-peptide, PDX-
1, and MafA were not found in the control cells. Magnification 1,000×. Immunofluorescent staining for DAPI 
(blue), insulin (green) with C-peptide (red), PDX-1 (red), or MafA (red). Additional images are provided in 
Supplementary Fig. S3. All images were acquired with an Olympus FluoViewTM FV1000 confocal microscope. 
(B) Gene expression analysis of primed cells harvested after 3 and 6 days of maintenance in the absence of CM, 
compared with syngeneic (MIN-6) or xenogeneic (INS-1) β-cells as well as freshly isolated murine BMNCs. 
CM-primed BMNCs still expressed β-cell markers (insulin-2, Ngn3, PDX-1, MafA, Nkx6.1, Nkx2.2, and Gck) 
but not glucagon. Data are presented as mean ± S.E.M. of three independent experiments. *p < 0.05 for primed 
cells versus BMNCs.
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Figure 4. Systemic infusion of primed BMNCs improves hyperglycemia in STZ-induced diabetic mice. (A) 
Summarized scheme of animal experiments. Male C57BL/6 mice were injected with STZ (I.P.) and two insulin 
pellets were transplanted subcutaneously for 14 days beginning 3 days after the STZ injection, followed by 
monitoring for 70 days. After 6 days, primed MIP-Luc/GFP mouse BMNCs (3 × 106 cells/mouse) were infused 
through the tail vein. (B) Body weight (left panel) and changes in random feeding blood glucose levels (right 
panel) of mice transplanted with primed cells (black filled circle for INS-1, n = 8; red filled triangle for MIN-6, 
n = 3) or comparable control cells (black empty circle for INS-1, n = 7; red empty triangle for INS-1, n = 3). 
(C) Blood glucose responses from the intraperitoneal glucose tolerance test (IPGTT). IPGTT (i.p. glucose 
(2 g/kg) injection) was performed after an overnight fast at 56 days after transplantation. Data are presented 
as mean ± S.E.M. *p < 0.05 for primed cells versus BMNCs (D) Representative immunofluorescent images of 
the pancreas and small intestines harvested 64 days after transplantation. Note the appearance of insulin and 
GFP double positive cells in the pancreas (arrow in the 1st panel from the left). Some of the cells present in 
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A growing literature thus demonstrates that IPCs can be produced from the gut or intestinal cells38–40, suggesting 
that the intestine is an accessible and abundant source of functional insulin-producing cells.
In the present study, we established a simple and effective protocol for differentiation of IPCs from BMNCs 
using β-cell-derived CM; however, CM or MPs are difficult to standardize. Moreover, MPs are able to mediate 
various unexpected pathophysiological fate changes in the stem cells46. Therefore, identification of the key com-
ponents enclosed by or integrated into MPs shed from the β-cells might improve IPC differentiation efficiency 
by eliminating unwanted pathophysiological effects from other contaminated components. Additionally, identi-
fication of the components that direct the differentiation may enable us to generate BMNC-derived IPCs to treat 
DM more efficiently by minimizing the ex vivo manipulation requirements. Nevertheless, the methods that are 
effective in mice are not always effective in humans, and considerable research remains to be conducted to achieve 
the therapeutic goals for DM, although our novel approach to the generation of IPCs from BMNCs has potential 
for the development of a treatment for diabetic patients.
Methods
Animals. C57BL/6-Tg [(Ins2-luc/EGFP/TK) 300Kauf/J; Jackson Laboratories stock #012943, referred to as 
MIP-Luc/GFP in this study)] and wild type C57BL/6 mice (Orient-Bio Co. Ltd., Seoul, Korea) were maintained 
in our facility. Both strains were housed in a specific pathogen free zone under adequate temperature (23 ± 3 °C) 
and relative humidity (55 ± 5%) with a 12 h light/12 h dark cycle, and received autoclaved food and water ad libi-
tum. All animal experiments were approved by the Animal Care and Use Committee (IACUC) of the Institute of 
Laboratory Animal Resources, Seoul National University, in accordance with the approved guidelines. MIP-Luc/
GFP mice carried the tri-fusion transgene luciferase (Luc)/enhanced green fluorescent protein (EGFP)/thymidine 
kinase (TK) under the control of the mouse insulin-2 promoter. Transgene expression was determined by Luc 
enzymatic activity and GFP expression was exclusive to β-cells in the pancreatic islets. All efforts were made to 
minimize animal suffering as well as the number of animals used.
Chimeric mice. Chimeric mice were generated by transferring BMNCs (1 × 106 cells/mouse) from MIP-Luc/
GFP mice into lethally (1,000 cGy) irradiated C57BL/6 mice (8–12 weeks old) via the tail vein. BMNCs were iso-
lated from tibiae and femurs by flushing with Hank’s Balanced Salt Solution (HBSS). Chimeric mice were used for 
experiments 4 weeks after BM reconstitution.
Cell sources. BMNC were prepared by flushing the femurs and tibias of MIP-Luc/GFP or wild type C57BL/6 
mice. Whole BMNC were suspended in BD Pharm Lyse buffer (BD Biosciences, San Jose, CA) to remove RBCs, 
washed, and resuspended in the appropriate media for further experiments. MIN-6, a cloned pancreatic β-cell 
line from C57BL/6 mice, was cultured in DMEM medium (Hyclone #SH30243) supplemented with 10% fetal 
bovine serum (FBS, Gibco #26140-079), and 1% antibiotics (Gibco #15140122). INS-1, a cloned pancreatic β-cell 
line established from rats, was maintained in RPMI 1640 medium (Welgene #LM011-01) supplemented with 10% 
FBS and antibiotics. bEND.3, an endothelial cell line established from mice, was purchased from ATCC (#CRL-
2299) and cultured in DMEM (Hyclone #SH30243) supplemented with 10% FBS and antibiotics.
Diabetes induction. Diabetes was induced by a single I.P. injection of 150 mg/kg STZ (Sigma-Aldrich 
#S0130). Blood glucose levels in the mice were monitored using a standard glucometer (Accu-Chek Active; Roche 
Diagnostics, Mannheim, Germany) and blood from a tail pinprick. In some experiments, slow-release insulin 
pellets (LinBit; Linshin Canada; Toronto, ON, Canada) were implanted subcutaneously in the diabetic mice for 
14 days beginning 3 days after the STZ injection to control the glucose levels.
Intraperitoneal glucose tolerance test. Mice were fasted for 18 hrs and administered an I.P. injection 
glucose (2.0 g/kg body weight). Blood glucose levels were measured at the indicated times after glucose injection.
Preparation of conditioned media. MIN-6 (1 × 107), INS-1 (1 × 107), and bEND.3 (5 × 106) cells were 
briefly dispersed with complete media and attached for 24 hrs in a 100 mm cell culture dish. To expose cells to 
stress conditions, the culture media was exchanged with DMEM (Hyclone # SH30021) containing low glucose 
(1,000 mg/L) supplemented with 1% FBS and antibiotics and maintained for an additional 72 hrs in the same 
incubator. Culture supernatants were collected, centrifuged at 1,200 rpm for 5 min to eliminate the pellet, passed 
through a 0.45 μm syringe filter to obtain standard CM, and stored in aliquots at −80 °C for future use. CM from 
islets was prepared by same procedures from culture supernatant of isolated rat islets maintained in 2,000 IEQ/
ml for 72 hrs in stress-inducing media, as previously mentioned. In some experiment MP-deprived CM was used 
instead. MP- depleted CM was prepared by removing large particles from the standard CM using centrifugal filter 
units (Amicon Ultra-4 Centrifugal Filter Unit with an Ultracel-100 membrane, Millipore #UFC810008).
Transplantation of CM containing Matrigel. Matrigel grafts were prepared by mixing standard CM 
(100 μL) with the same volume of Matrigel (BD Matrigel Basement Membrane Matrix, BD Bioscience, San Jose, 
the lamina propria of the intestinal villi are insulin/GFP (arrow in the 2nd panel from the left), or insulin and 
C-peptide double positive (arrow in the 3rd panel from the left), but insulin and glucagon double positive cells 
were rare (arrow in the 4th panel from the left). GFP positive cells were not found in the pancreatic or small 
intestine tissues from control mice. All images were acquired with an Olympus FluoView FV1000 confocal 
microscope. Scale bars in low magnification (50 μm, upper panels), in high magnification (20 μm, lower panel).
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CA, USA), and transplanted into the subcutaneous space on the back of chimeric mice. Matrigel grafts were 
harvested on day 18 after transplantation, fixed, and embedded for immunofluorescence microscopic analysis.
Systemic infusion of primed BMNCs in diabetic mice. Male C57BL/6 mice were injected with STZ 
(I.P.) and two insulin pellets were transplanted subcutaneously for 14 days beginning 3 days after the STZ injec-
tion, followed by monitoring for 70 days. After 6 days, primed BMNCs of the MIP-Luc/GFP mice (3 × 106 cells/
mouse) were infused to the STZ-treated mice through the tail vein.
In vitro differentiation of murine BMNCs into IPCs. Whole BMNC were primed for 6 days in DMEM 
(Hyclone #SH30021) containing 10% FBS (final concentration) and 50% CM in suspension (primed BMNCs) 
in the absence of any supplements that are known to be essential to IPC differentiation. For characterization, 
primed BMNCs were washed twice with PBS and further maintained 3–6 days in DMEM (Hyclone #SH30243) 
containing 10% FBS and antibiotics under static condition (in vitro maintained BMNCs) as described in Fig. 2A.
Reverse transcriptase polymerase chain reaction (RT-PCR) and quantitative real-time PCR 
(qPCR). Total RNA was extracted from undifferentiated BMNCs and from primed BMNCs using the TRIzol 
Reagent (Invitrogen). Total RNA (500 µg) was reverse transcribed into first-strand cDNA using SuperScript 
II Reverse Transcriptase (Promega) according to the manufacturer’s instructions. RT-PCR was performed to 
amplify each cDNA using the AccuPower PCR premix (Promega). PCR products were separated on 1.5% agarose 
gel and stained with Dyne LoadingSTAR (DYNEBIO, A750). Q-PCR was performed using SYBR Premix Ex 
Taq (Takara, Shiga, Japan) and a LightCycler 96 (Light Cycler 96; Roche, Mannheim, Germany). The hypox-
anthine phosphoribosyl transferase (HPRT) mRNA level was used as the internal control. Relative expression 
levels were calculated using the 2−ΔΔCt method after normalization to β-actin. The primer sequences are shown 
in Supplementary Table 3.
Flow cytometry. Prepared cells were washed twice in staining buffer (HBSS containing 2% FBS). To quantify 
the GFP expressing cells controlled by insulin-2 promoter activation, primed BMNC were washed twice with PBS 
and incubated with the specific antibodies (CD45-APC, eBioscience #17-0451) for 30 min at 4 °C. Flow cytometry 
was performed using a BD LSR II instrument (Becton Dickinson) with subsequent analysis using the FlowJo data 
analysis software (FlowJo, Ashland, OR) with at least 50,000 events being acquired.
Measurement of secreted insulin. The culture media from primed cells was replaced with high glucose 
containing DMEM (Hyclone #SH30243) supplemented with 10% FBS and antibiotics. After 3 days, the super-
natants were collected and insulin levels were measured using an insulin immunoassay kit (ALPCO, Salem, NH, 
USA) according to the manufacturer’s instructions.
Immunofluorescent staining. Sectioned tissues or paraformaldehyde fixed cells were washed three times 
with PBS, then blocked with PBS containing 5% normal goat serum (NGS) and 0.3% Triton X-100 for 15 min. 
After blocking, the cells were incubated with primary antibodies (Supplementary Table 2) in 2.5% NGS over-
night at 4 °C. The next day, the cells were washed three times with PBS-Tween 20 (PBS-T, 0.01%), and then 
incubated with secondary antibodies in 2.5% NGS for 1 hr at room temperature. Cells were counterstained with 
4,6-diamidino-2-phenyldole (DAPI; 1:2,500; Molecular Probe), and an Olympus FluoView FV1000 confocal 
microscope fitted with the appropriate filters was used to obtain the images.
Western blot analysis. Cell lysates were prepared in lysis buffer containing 20 mM Tris-HCl (pH 7.4), 
1% NP-40, 10 mM Na4P2O7, 5 mM EDTA, 100 mM NaF, 2 mM Na3VO4, 7 μg/mL leupeptin, 7 μg/mL apro-
tinin, and 1 mM phenylmethylsulfonyl fluoride. Whole-cell lysates were subjected to sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins on the gel were transferred onto a nitrocellulose 
membrane. The membranes were incubated in blocking solution (5% skim milk) and then with specific primary 
antibodies in 0.1% Tween® 20-Tris-buffered saline. Hybridized primary antibodies were detected using a horse-
radish peroxidase-conjugated IgG antibody (Santa Cruz Biotechnology). Bands were detected using an enhanced 
chemiluminescence kit (Thermo, Rockford, IL, USA).
Statistical analysis. Statistical analysis was performed with the Statistical Analysis System (SAS) soft-
ware package (version 9.3; SAS Institute, Cary, NC). Insulin secretion and gene expression were analyzed by 
non-parametric repeated measures ANOVA. Changes in body weight and blood glucose levels, including IPGTT, 
were analyzed for each cage by mixed effects regression models that fitted random effects for animals and fixed 
effects for time, group and an interaction of time. If the interaction was not-significant, the interaction term was 
removed and the model was rerun. Bonferroni corrections were used to adjust p-values for multiple testing. 
Two-sided p-values of < 0.05 were considered statistically significant. Data were expressed as mean ± S.E.M.
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